Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02520323 · ClinicalTrials.gov registry record
The Lung Microbiome in Sarcoidosis
A clinical trial, sponsored by University of Michigan.
- Completed
- Registry status
- 21
- Enrollment target
NCT02520323 is a clinical trial that has completed, run by University of Michigan. The registered enrollment target is 21 participants.
The verdict
NCT02520323 has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
Study Summary
The objective of this study is to determine the presence of bacterial species, and the immunologic and molecular mechanisms of granuloma formation that might be involved in the pathogenesis of sarcoidosis. The investigators will collect peripheral blood and bronchoalveolar lavage fluid samples to isolate bacterial DNA and blood monocytes and lymphocytes. Specimens will be obtained from patients with sarcoidosis, with non-sarcoid lung disease, and healthy volunteers to directly compare the bacterial species present and the characteristics of cells thought to be involved in granuloma formation.
Interventions
- OTHER Blood draw
- BEHAVIORAL Questionnaires
- PROCEDURE Bronchoscopy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2015-06 |
| Est. Completion | 2017-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02520323
The ClinicalTrials.gov registry entry for NCT02520323 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Blood draw is the first listed.
NCT02520323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02520323 about?
NCT02520323 is a clinical study titled "The Lung Microbiome in Sarcoidosis". The objective of this study is to determine the presence of bacterial species, and the immunologic and molecular mechanisms of granuloma formation that might be involved in the pathogenesis of sarcoidosis. The investigators will collect peripheral blood and bronchoalveolar lavage fluid samples to is...
What is the current status of trial NCT02520323?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2015-06. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02520323?
The interventions under investigation include: Blood draw (OTHER), Questionnaires (BEHAVIORAL), Bronchoscopy (PROCEDURE).
Who is sponsoring clinical trial NCT02520323?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.